May 20, 2024

Formulation Development Outsourcing Market Size To Cross USD 75.8 Bn By 2032

The global formulation development outsourcing market size accounted for US$ 37.4  Bn in 2022 and is projected to reach around USD 75.8 Bn by 2032, growing at a CAGR of 7.32% from 2023 to 2032.

Formulation Development Outsourcing Market Size 2023 To 2032


Key Takeaways:

  • By region, Asia- Pacific contributed more than 41% of revenue share in 2022, the region is anticipated to register the fastest growth rate during the forecast period.
  • By service, the formulation development generated over 77% of revenue share in 2022.
  • By formulation, the oral segment had the largest market share of 64% in 2022.
  • By therapeutic area, the oncology segment carried the largest market share of 26% in 2022, the segment is expected to sustain its position during the forecast period.
  • By end-user, the pharmaceutical industry segment is expected to be dominant in the market during the predicted period.

Report Summary

The global formulation development outsourcing market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the formulation development outsourcing market across the globe.

A comprehensive estimate on the formulation development outsourcing market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of formulation development outsourcing during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3192

 Formulation Development Outsourcing Market Report Scope 

Report CoverageDetails
Market Size in 2023USD 40.14 Billion
Market Size by 2032USD 75.8 Billion
Growth Rate from 2023 to 2032CAGR of 7.32%
Largest MarketAsia Pacific
Base Year2022
Forecast Period2023 To 2032
Segments CoveredBy Service, By Formulation, By Therapeutic Area, and By End-User
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized formulation development outsourcing market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Carbonated Beverage Market Size To Cross USD 654.37 Bn By 2032

 Formulation Development Outsourcing Market Players

The report includes the profiles of key formulation development outsourcing market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • SGS S.A.
  • Eurofins Scientific SE
  • Element
  • Labcorp
  • Thermo Fisher Scientific, Inc. (Patheon)
  • Intertek Group plc
  • Recipharm
  • Lonza
  • Charles River Laboratories International, Inc.
  • Catalent Inc.

Market Segmentation

By Service

  • Preformulation
  • Formulation Development

By Formulation

  • Topical
  • Oral
  • Injectable
  • Others

By Therapeutic Area

  • Oncology
  • Infectious Disease
  • Respiratory
  • Cardiovascular
  • Neurology
  • Hematology
  • Dermatology
  • Others

By End-User

  • Pharmaceutical Industries
  • Research and Academic Institutions

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Formulation Development Outsourcing Market 

5.1. COVID-19 Landscape: Formulation Development Outsourcing Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Formulation Development Outsourcing Market, By Service

8.1. Formulation Development Outsourcing Market, by Service, 2023-2032

8.1.1. Preformulation

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Formulation Development

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Formulation Development Outsourcing Market, By Formulation

9.1. Formulation Development Outsourcing Market, by Formulation, 2023-2032

9.1.1. Topical

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Oral

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Injectable

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Formulation Development Outsourcing Market, By Therapeutic Area 

10.1. Formulation Development Outsourcing Market, by Therapeutic Area, 2023-2032

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Infectious Disease

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Respiratory

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Cardiovascular

10.1.4.1. Market Revenue and Forecast (2020-2032)

10.1.5. Neurology

10.1.5.1. Market Revenue and Forecast (2020-2032)

10.1.6. Hematology

10.1.6.1. Market Revenue and Forecast (2020-2032)

10.1.7. Dermatology

10.1.7.1. Market Revenue and Forecast (2020-2032)

10.1.8. Others

10.1.8.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Formulation Development Outsourcing Market, By End-User 

11.1. Formulation Development Outsourcing Market, by End-User, 2023-2032

11.1.1. Pharmaceutical Industries

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Research and Academic Institutions

11.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Formulation Development Outsourcing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.4. Market Revenue and Forecast, by End-User (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.6.4. Market Revenue and Forecast, by End-User (2020-2032)

Chapter 13. Company Profiles

13.1. SGS S.A.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Eurofins Scientific SE

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Element

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Labcorp

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Thermo Fisher Scientific, Inc. (Patheon)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Intertek Group plc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Recipharm

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Lonza

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Charles River Laboratories International, Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Catalent Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com